CurrentEndo
Get Weekly

Topic · page 3 of 12

Lipids & metabolic liver disease

Lipid disorders and metabolic dysfunction-associated steatotic (fatty) liver disease, as published in the endocrine journals

Briefs 81–120 of 460 placed here, newest publication first

Briefs in Lipids & metabolic liver disease

Newest publication first

  1. Cardiovasc Diabetol

    Joint associations of anthropometric indices and C-reactive protein-triglyceride-glucose index with incident hypertension: a stratified analysis by blood pressure level from the CHARLS, 2011–2020

    Cohort study

  2. J Clin Endocrinol Metab

    Patients with MASLD exhibit in vivo changes in hepatic response to oral fructose consumption

    Mechanistic study

  3. Cardiovasc Diabetol

    Associations of cumulative exposure and dynamic trajectories of cholesterol-HDL-glucose (CHG) index with cardiovascular disease in middle-aged and older Chinese adults: a longitudinal analysis

    Cohort study

  4. Endocr Pract

    Low Serum Insulin-Like Growth Factor-1 as a Predictor of Fibrosis Burden in Metabolic-Associated Fatty Liver Disease

    Cross-sectional study

  5. Diabetes Obes Metab

    Integrated Plasma Proteomics and Functional Analyses Reveal Hepatic CDHR2 as a Potential Therapeutic Target in MASLD

    Mechanistic study

  6. Cardiovasc Diabetol

    Comprehensive evaluation of triglyceride glucose index–a body shape index (TyG–ABSI) for incident peripheral artery disease: data-driven phenotyping and machine learning-based risk prediction in the UK Biobank

    Cohort study

  7. Cardiovasc Diabetol

    Association of the C-reactive protein–triglyceride–glucose index with metabolic dysfunction-associated steatotic liver disease and long-term all-cause and cardiovascular mortality: evidence from two nationwide prospective cohort studies

    Cross-sectional study

  8. JAMA Netw Open

    Liver Stiffness Measurement and All-Cause Mortality in Individuals With Diabetes

    Cohort study

  9. Diabetes Obes Metab

    Identification of Common Blood Metabolic Derangements Using Magnetic Resonance Signatures of the Pancreas and Liver

    Cross-sectional study

  10. Cardiovasc Diabetol

    The cholesterol, high-density lipoprotein, and glucose (CHG) index as a novel metabolic marker for predicting adverse outcomes in myocardial infarction survivors: insights from two large prospective cohorts

    Cohort study

  11. Cardiovasc Diabetol

    Triglyceride glucose index—a body shape index (TyG-ABSI) outperforms traditional obesity indices in predicting all-cause and cardiovascular mortality in metabolic-dysfunction associated steatotic liver disease: the mediating role of biological aging

    Cohort study

  12. Cardiovasc Diabetol

    Association between estimated glucose disposal rate and cause-specific mortality among individuals with metabolic dysfunction-associated steatotic liver disease

    Cohort study

  13. Diabetes Obes Metab

    Associations between use of aspirin and magnetic resonance imaging‐derived liver fat and fibroinflammation

    Cohort study

  14. Endocr Pract

    Fasting Plasma Glucose Mediates the Association Between the Atherogenic Index of Plasma and Depression in US Adults: A Study From NHANES 2005-2020

    Cross-sectional study

  15. Diabet Med

    Association between diabetes and in‐hospital outcomes in patients with metabolic dysfunction‐associated steatotic liver disease hospitalized for cardiovascular disease: A nationwide database study

    Cross-sectional study

  16. Cardiovasc Diabetol

    The association of C-reactive protein–triglyceride–glucose index with cardiometabolic multimorbidity in middle-aged and older adults: evidence from two cohort studies

    Cohort study

  17. Endocr Pract

    Safety and Efficacy of Oral PCSK9 Inhibitors in Hypercholesterolemia: A Systematic Review and Network Meta-Analysis

    Meta-analysis

  18. Pediatr Obes

    Endotoxin Markers Are Elevated in Adolescents With Obesity With and Without Metabolic Dysfunction‐Associated Steatotic Liver Disease

    Cross-sectional study

  19. Diabetes Obes Metab

    Impact of conventional lipid‐lowering therapy on circulating levels of p roprotein convertase subtilisin/kexin type 9: A systematic review and meta‐analysis of randomised controlled trials

    Meta-analysis

  20. Cardiovasc Diabetol

    Association of the triglyceride glucose-Chinese visceral adiposity index with incident cardiometabolic multimorbidity in middle-aged and older adults: a nationwide prospective cohort study

    Cohort study

  21. Cardiovasc Diabetol

    Predictive value of an integrated insulin resistance and lipometabolic score for cardiometabolic multimorbidity in older adults: a UK cohort study

    Cohort study

  22. J Clin Endocrinol Metab

    Integrative genetic and liver transcriptomic analyses identify TRIB1AL as a target for steatotic liver disease

    Meta-analysis

  23. Diabetes Obes Metab

    Association of four insulin resistance indices with liver‐related adverse outcomes: A prospective cohort study

    Cohort study

  24. Cardiovasc Diabetol

    Association of atherogenic index of plasma and cardiometabolic index with all-cause mortality and cardiovascular disease in NAFLD patients: NHANES 1999–2018

    Cross-sectional study

  25. Endocr Pract

    The Impact of the Ketogenic Diet on the Lipid Profile in Adults: A Comprehensive Review and Meta-Regression Analysis of Randomized Controlled Trials

    Meta-analysis

  26. Cardiovasc Diabetol

    Measures of comorbid cardiometabolic burden and cardiovascular disease risk in people with MRI-confirmed steatotic liver disease: a prospective cohort study

    Cohort study

  27. Endocr Pract

    Implications of Expanded Advanced Fibrosis Screening Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease in Primary Care

    Cross-sectional study

  28. Lancet Diabetes Endocrinol

    Efficacy and safety of inclisiran in adolescents with heterozygous familial hypercholesterolaemia (ORION-16): a two-part, randomised, multicentre clinical trial

    Randomized controlled trial

  29. BMJ Open Diabetes Res Care

    Serum soluble ASGR1 concentration is elevated in patients with metabolic dysfunction-associated steatotic liver disease and is associated with adiponectin

    Case-control study

  30. Cardiovasc Diabetol

    Association between the triglyceride-glucose-frailty index and all-cause and cardiovascular mortality in individuals with cardiovascular-kidney-metabolic syndrome: the mediating role of the poverty-income ratio

    Cohort study

  31. Cardiovasc Diabetol

    Association between the combined c-reactive protein-triglyceride glucose index and hypertension with long-term stroke among cardiovascular-kidney-metabolic syndrome stages 0–3 population: a nationwide prospective cohort study

    Cohort study

  32. Cardiovasc Diabetol

    Prospective associations of triglyceride-glucose related indices with cardiovascular disease and mortality in individuals with metabolic syndrome: evidence from the UK biobank

    Cohort study

  33. Cardiovasc Diabetol

    Triglyceride-glucose-related indices and cardiovascular outcomes in individuals with pre-frailty or frailty: insights from a prospective cohort analysis using UK Biobank data

    Cohort study

  34. Cardiovasc Diabetol

    Association of cumulative cholesterol-HDL-glucose index with blood pressure changes and risk of new-onset hypertension in middle-aged and older adults: a cohort study

    Cohort study

  35. Cardiovasc Diabetol

    Prognostic effect of triglyceride glucose-related parameters on all-cause and cardiovascular mortality in individuals with cardiovascular-kidney-metabolic syndrome: evidence from international multi-cohort studies

    Cohort study

  36. Cardiovasc Diabetol

    Association of cholesterol, high-density lipoprotein and glucose (CHG) index with mortality risk in metabolic dysfunction-associated steatotic liver disease (MASLD) adults: results from two prospective cohorts

    Cohort study

  37. Cardiovasc Diabetol

    Joint assessment of insulin resistance surrogate indices and basal metabolic rate for primary prevention of cardiometabolic multimorbidity: evidence from the China Health and Retirement Longitudinal Study (2011–2020)

    Cohort study

  38. Cardiovasc Diabetol

    Relationship between nine triglyceride-glucose-related indices and cardiometabolic multimorbidity incidence in patients with cardiovascular-kidney-metabolic syndrome stage 0–3: a nationwide prospective cohort study

    Cohort study

  39. Diabetes Obes Metab

    Population‐based cohort validation and replication reveals limited generalizability of cluster‐based MASLD subtypes

    Cohort study

  40. Diabetes Res Clin Pract

    The burden and mortality impact of cardiovascular disease–metabolic dysfunction–associated steatotic liver disease comorbidity

    Cross-sectional study

All 460 Briefs in ExploreShowing Briefs 81–120 of 460, newest first